CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ehinger, M.
Right arrow Articles by Gullberg, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ehinger, M.
Right arrow Articles by Gullberg, U.

Cell Growth & Differentiation, Vol 6, Issue 1 9-17, Copyright © 1995 by American Association of Cancer Research


ARTICLES

Involvement of the tumor suppressor gene p53 in tumor necrosis factor-induced differentiation of the leukemic cell line K562

M Ehinger, E Nilsson, AM Persson, I Olsson and U Gullberg
Department of Medicine, University of Lund, Sweden.

The cDNA of the human wild-type p53 tumor suppressor gene was constitutively overexpressed in the leukemic cell line K562 (which lacks detectable amounts of p53 protein) in order to investigate the consequences for growth and differentiation. Several stable clones were established by transfection of the expression vector pc53SN3. Expression of p53 protein was characterized by biosynthetic labeling and immunoprecipitation with the monoclonal antibodies pAb 1801 (reacting with wild-type and mutant human p53), pAb 240 (reacting with mutant human p53) and pAb 1620 (reacting with wild-type human p53). All clones which were 1801+, 240-, 1620- or 1801+, 240-, 1620+ were defined as "wild-type-like p53-expressing" clones. Our results show that expression of p53 protein is compatible with continuous proliferation of K562 cells. The growth characteristics of wild-type-like p53-expressing clones did not differ from that of control clones. However, the former were more sensitive than p53-negative control clones to growth inhibition by tumor necrosis factor (TNF), a cytokine with a potential role in growth and differentiation of myeloid leukemic cells. In addition, a 2- to 4-fold increase of the amount of hemoglobin, a marker of erythroid differentiation, was observed when wild-type-like p53 protein-expressing clones were incubated with TNF. This suggests that differentiation is the mechanism responsible for the increased TNF sensitivity of these clones. Our results support a role for p53 in mediating growth inhibitory and differentiation inducing signals by TNF.


This article has been cited by other articles:


Home page
J Biol ChemHome page
P. G. Fuhrken, P. A. Apostolidis, S. Lindsey, W. M. Miller, and E. T. Papoutsakis
Tumor Suppressor Protein p53 Regulates Megakaryocytic Polyploidization and Apoptosis
J. Biol. Chem., June 6, 2008; 283(23): 15589 - 15600.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
K. L. Kathrein, R. Lorenz, A. M. Innes, E. Griffiths, and S. Winandy
Ikaros Induces Quiescence and T-Cell Differentiation in a Leukemia Cell Line
Mol. Cell. Biol., March 1, 2005; 25(5): 1645 - 1654.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
K. N. Pennington, J. A. Taylor, G. D. Bren, and C. V. Paya
I{kappa}B Kinase-Dependent Chronic Activation of NF-{kappa}B Is Necessary for p21WAF1/Cip1 Inhibition of Differentiation-Induced Apoptosis of Monocytes
Mol. Cell. Biol., March 15, 2001; 21(6): 1930 - 1941.
[Abstract] [Full Text] [PDF]


Home page
Cell Growth Differ.Home page
K. Chylicki, M. Ehinger, H. Svedberg, and U. Gullberg
Characterization of the Molecular Mechanisms for p53-mediated Differentiation
Cell Growth Differ., November 1, 2000; 11(11): 561 - 571.
[Abstract] [Full Text]


Home page
Cell Growth Differ.Home page
K. Chylicki, M. Ehinger, H. Svedberg, G. Bergh, I. Olsson, and U. Gullberg
p53-mediated Differentiation of the Erythroleukemia Cell Line K562
Cell Growth Differ., June 1, 2000; 11(6): 315 - 324.
[Abstract] [Full Text]


Home page
BloodHome page
G. Darnell and D.R. Richardson
The Potential of Iron Chelators of the Pyridoxal Isonicotinoyl Hydrazone Class as Effective Antiproliferative Agents III: The Effect of the Ligands on Molecular Targets Involved in Proliferation
Blood, July 15, 1999; 94(2): 781 - 792.
[Abstract] [Full Text] [PDF]


Home page
EMBO J.Home page
K. Sabapathy, M. Klemm, R. Jaenisch, and E. F. Wagner
Regulation of ES cell differentiation by functional and conformational modulation of p53
EMBO J., October 15, 1997; 16(20): 6217 - 6229.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Bergh, M. Ehinger, T. Olofsson, B. Baldetorp, E. Johnsson, H. Brycke, G. Lindgren, I. Olsson, and U. Gullberg
Altered Expression of the Retinoblastoma Tumor-Suppressor Gene in Leukemic Cell Lines Inhibits Induction of Differentiation But Not G1-Accumulation
Blood, April 15, 1997; 89(8): 2938 - 2950.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1995 by the American Association of Cancer Research.